The Effect of Nanocurcumin Supplementation on Inflammatory and Biochemical Indicators in Hospitalized Patients With COVID-19: A Randomized Controlled Clinical Trial
{"title":"The Effect of Nanocurcumin Supplementation on Inflammatory and Biochemical Indicators in Hospitalized Patients With COVID-19: A Randomized Controlled Clinical Trial","authors":"Sedigheh Ahmadi, Mohsen Mohit, Zeinab Mehrabi, Mohammad Reza Heydari, Seyed Nooreddin Faraji, Shoeleh Yaghoubi, Morteza Zare, Seyed Jalil Masoumi","doi":"10.1155/ijcp/6675459","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background:</b> The prior studies showed that nanocurcumin (NC) has potential anti-viral properties against a wide range of viral infections, making it a promising candidate for treating COVID-19. This study aimed to investigate the effect of NC supplementation on the acute phase proteins, including interleukin-6 (IL-6), C-reactive protein (CRP), albumin (ALB) and Erythrocyte Sedimentation Rate (ESR), and biochemical markers including lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine transaminase (ALT) and complete blood cells (CBC) in the hospitalized patients with Coronavirus disease 2019 (COVID-19).</p>\n <p><b>Methods and Materials:</b> In a double-blind placebo-controlled clinical trial conducted at Ali-Asghar Hospital of Shiraz University of Medical Sciences, 76 COVID-19 patients with mild to moderate disease severity were randomly assigned to two groups. All patients received the national treatment guideline for COVID-19. The intervention group was administered 160 mg/day of NC for a period of 2 weeks. Blood samples were obtained at the start and the end of the research, and nutritional consumption was determined using a 24 h dietary recall.</p>\n <p><b>Results:</b> The mean age of participants in the NC and placebo groups was 54.69 ± 13.44 and 53.94 ± 11.62 years, respectively. In the NC group, compared with placebo group, the levels of IL-6 (<i>p</i> = 0.017) and LDH (<i>p</i> = 0.004) was significantly reduced. There was no significant difference in the mean changes of AST (<i>p</i> = 0.197), ALT (<i>p</i> = 0.086), ALB (<i>p</i> = 0.560), CRP (<i>p</i> = 0.197), ESR (<i>p</i> = 0.298), hemoglobin (Hb) (<i>p</i> = 0.372), white blood cells (WBC) (<i>p</i> = 0.995), neutrophils (<i>p</i> = 0.264), and lymphocyte (<i>p</i> = 0.418) between two groups.</p>\n <p><b>Conclusion:</b> According to the research results, it seems that adding NC supplementation to the treatment plan for COVID-19 patients who are hospitalized and have mild to moderate illness severity might possibly reduce inflammation.</p>\n <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: IRCT20211126053183N1.</p>\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2024 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ijcp/6675459","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ijcp/6675459","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The prior studies showed that nanocurcumin (NC) has potential anti-viral properties against a wide range of viral infections, making it a promising candidate for treating COVID-19. This study aimed to investigate the effect of NC supplementation on the acute phase proteins, including interleukin-6 (IL-6), C-reactive protein (CRP), albumin (ALB) and Erythrocyte Sedimentation Rate (ESR), and biochemical markers including lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine transaminase (ALT) and complete blood cells (CBC) in the hospitalized patients with Coronavirus disease 2019 (COVID-19).
Methods and Materials: In a double-blind placebo-controlled clinical trial conducted at Ali-Asghar Hospital of Shiraz University of Medical Sciences, 76 COVID-19 patients with mild to moderate disease severity were randomly assigned to two groups. All patients received the national treatment guideline for COVID-19. The intervention group was administered 160 mg/day of NC for a period of 2 weeks. Blood samples were obtained at the start and the end of the research, and nutritional consumption was determined using a 24 h dietary recall.
Results: The mean age of participants in the NC and placebo groups was 54.69 ± 13.44 and 53.94 ± 11.62 years, respectively. In the NC group, compared with placebo group, the levels of IL-6 (p = 0.017) and LDH (p = 0.004) was significantly reduced. There was no significant difference in the mean changes of AST (p = 0.197), ALT (p = 0.086), ALB (p = 0.560), CRP (p = 0.197), ESR (p = 0.298), hemoglobin (Hb) (p = 0.372), white blood cells (WBC) (p = 0.995), neutrophils (p = 0.264), and lymphocyte (p = 0.418) between two groups.
Conclusion: According to the research results, it seems that adding NC supplementation to the treatment plan for COVID-19 patients who are hospitalized and have mild to moderate illness severity might possibly reduce inflammation.
期刊介绍：
IJCP is a general medical journal. IJCP gives special priority to work that has international appeal.
IJCP publishes:
Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion]
Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion]
Study design and interpretation. Example. [Always peer reviewed]
Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed]
Meta-analyses. [Always peer reviewed]
Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed]
Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed]
''How to…'' papers. Example. [Always peer reviewed]
Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed]
Letters. [Peer reviewed at the editor''s discretion]
International scope
IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
